ASCEND

LEO Pharma to Maintain Leadership Role at AAD in 2024 with New Late-Breaking Data Spanning Multiple Therapeutic Areas

Retrieved on: 
Wednesday, March 6, 2024

LEO Pharma A/S, a global leader in medical dermatology, will present a breadth of new data on moderate-to-severe chronic hand eczema (CHE), congenital ichthyosis (CI) and atopic dermatitis (AD) at the upcoming 82nd American Academy of Dermatology (AAD) Annual Meeting.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, will present a breadth of new data on moderate-to-severe chronic hand eczema (CHE), congenital ichthyosis (CI) and atopic dermatitis (AD) at the upcoming 82nd American Academy of Dermatology (AAD) Annual Meeting.
  • The event is being held from March 8th to 12th in San Diego, California.
  • “Our growing body of clinical evidence reinforces our passion and commitment to advancing the standard of care in medical dermatology,” said Kreesten Meldgaard Madsen, LEO Pharma’s Chief Development Officer.
  • I am proud that we can follow up on our 2023 AAD program with this level of critical data,” said Brian Hilberdink, EVP and President, Region North America, LEO Pharma.

BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Retrieved on: 
Thursday, February 29, 2024

The analysis suggests a progression-free survival and complete response advantage for BRUKINSA versus acalabrutinib, as well as potentially improved overall survival.

Key Points: 
  • The analysis suggests a progression-free survival and complete response advantage for BRUKINSA versus acalabrutinib, as well as potentially improved overall survival.
  • These data will be presented during the 28th Annual International Congress on Hematologic Malignancies® in Miami from February 29 - March 3.
  • “Head-to-head randomized clinical trials are the gold standard when it comes to evaluating the potential impact of individual treatments for patients.
  • The global BRUKINSA development program includes more than 5,000 subjects enrolled to date in 29 countries and regions.

Enerpac Tool Group Announces Chief Financial Officer Transition

Retrieved on: 
Thursday, February 8, 2024

Enerpac Tool Group Corp. (NYSE: EPAC) (the “Company” or “Enerpac”) today announced that Anthony Colucci is stepping down as Executive Vice President and Chief Financial Officer to assume an executive role at a private equity firm.

Key Points: 
  • Enerpac Tool Group Corp. (NYSE: EPAC) (the “Company” or “Enerpac”) today announced that Anthony Colucci is stepping down as Executive Vice President and Chief Financial Officer to assume an executive role at a private equity firm.
  • He will remain as CFO through March 1, 2024, to assist with the transition.
  • In the interim, P. Shannon Burns has been appointed as Interim Principal Financial Officer and Patrick Dawson has been appointed as Interim Principal Accounting Officer.
  • Prior to joining Enerpac, Mr. Burns served in financial leadership roles at Harley-Davidson, Inc., including three years as Head of Investor Relations.

Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting

Retrieved on: 
Monday, December 11, 2023

NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced new data that treatment with Auvelity® (dextromethorphan-bupropion) was associated with improvement in quality of life outcomes in broad populations of depression patients in the EVOLVE open-label trial in major depressive disorder (MDD). These new data were presented at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting, held in Tampa, Florida, from Dec. 3-6, 2023.

Key Points: 
  • New data on Auvelity’s impact on quality of life, measured by the Q-LES-Q-SF, in patients who had received at least one prior treatment during their current depressive episode
    NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced new data that treatment with Auvelity® (dextromethorphan-bupropion) was associated with improvement in quality of life outcomes in broad populations of depression patients in the EVOLVE open-label trial in major depressive disorder (MDD).
  • These new data were presented at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting, held in Tampa, Florida, from Dec. 3-6, 2023.
  • An evaluation of interest and activity levels of individuals with MDD following treatment with Auvelity in a pooled post-hoc analysis of the placebo-controlled GEMINI and active-controlled ASCEND studies, and an analysis of potential withdrawal symptoms following discontinuation of Auvelity treatment in the GEMINI trial were also presented.
  • “Depression exacts an extraordinary impact on affected individuals especially by impairing enjoyment in activities and role function,” said Roger McIntyre, MD, FRCPC, Professor of Psychiatry and Pharmacology at the University of Toronto and lead author.

Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American

Retrieved on: 
Tuesday, November 28, 2023

At the hearing, among other things, the Court approved an initial $3.0 million in interim funding pursuant to a debtor-in-possession (“DIP”) financing facility.

Key Points: 
  • At the hearing, among other things, the Court approved an initial $3.0 million in interim funding pursuant to a debtor-in-possession (“DIP”) financing facility.
  • The Company may appeal the determination pursuant to Part 12 of the NYSE American Company Guide within seven calendar days of the Delisting Notice.
  • However, the Company does not intend to appeal this determination, and, therefore, it is expected that the Securities will be delisted.
  • As a result, the Company’s common stock is expected to begin trading on the over-the-counter market following such suspension of trading on the NYSE American.

Enerpac Tool Group Reports First Quarter Fiscal 2024 Results and Affirms Full-Year Guidance

Retrieved on: 
Tuesday, December 19, 2023

The Company repurchased approximately one million shares of its common stock in the first quarter of fiscal 2024 for $26 million under its share repurchase program announced in March 2022.

Key Points: 
  • The Company repurchased approximately one million shares of its common stock in the first quarter of fiscal 2024 for $26 million under its share repurchase program announced in March 2022.
  • “With the solid start to fiscal 2024, we are on track to achieve our full-year financial objectives,” concluded Sternlieb.
  • As such, the Company affirms its fiscal 2024 guidance, projecting a net sales range of $590 million to $605 million.
  • Webcast information and conference call materials, including an earnings presentation, are available on the Enerpac Tool Group company website ( www.enerpactoolgroup.com ).

Major Milestones Achieved Through the ISS National Lab in 2023

Retrieved on: 
Wednesday, December 20, 2023

In fiscal year 2023, more than 110 ISS National Lab-sponsored payloads were delivered to the orbiting laboratory—the most ever in a single year.

Key Points: 
  • In fiscal year 2023, more than 110 ISS National Lab-sponsored payloads were delivered to the orbiting laboratory—the most ever in a single year.
  • A wide range of research and technology development was conducted through the ISS National Lab this year.
  • Many ISS National Lab research successes have been highlighted in Upward, official magazine of the ISS National Lab , which serves to communicate valuable results to the scientific community.
  • To learn more about how to join the expanding ISS National Lab research community, visit the Current Opportunities page on our website .

Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease

Retrieved on: 
Monday, November 13, 2023

The ASCEND (A novel Selective Compound to ENable Individuals with Parkinson’s Disease) study will explore the potential use of CVN424 as a novel and innovative treatment option for individuals with early-stage Parkinson’s disease.

Key Points: 
  • The ASCEND (A novel Selective Compound to ENable Individuals with Parkinson’s Disease) study will explore the potential use of CVN424 as a novel and innovative treatment option for individuals with early-stage Parkinson’s disease.
  • "We are delighted to announce the commencement of our ASCEND study in individuals who have recently been diagnosed with Parkinson's disease and not yet received levodopa treatment," stated Craig Thompson, chief executive officer of Cerevance.
  • "This study aims to build upon the promising results from our previous Phase 2 trial of CVN424 as an adjunctive therapy for later-stage Parkinson's disease.
  • The Phase 2 ASCEND study is a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of CVN424 in individuals with early, untreated Parkinson’s disease.

Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 2, 2023

BASKING RIDGE, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced its financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Lisata and its development collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies, and RNA-based therapeutics.
  • The trial continues to make steady progress with enrollment completion expected by the fourth quarter of 2023 and data readouts expected in 2024.
  • We anticipate the first patient treated to be in the fourth quarter of 2023.
  • Lisata will hold a live conference call on Thursday, November 2, 2023, at 4:30 p.m. Eastern time to discuss financial results, provide a business update and answer questions.

Boryung Successfully Concludes 'Humans In Space Symposium' at 2023 ASCEND in Las Vegas

Retrieved on: 
Thursday, November 2, 2023

Boryung gains substantial interest from participating companies and institutions at ASCEND, paving the way for enhanced collaboration and exchange opportunities.

Key Points: 
  • Boryung gains substantial interest from participating companies and institutions at ASCEND, paving the way for enhanced collaboration and exchange opportunities.
  • SEOUL, South Korea and LAS VEGAS, Nov. 2, 2023 /PRNewswire/ -- Boryung, a leading healthcare investment company, has announced that it successfully hosted the Humans In Space (HIS) Symposium co-located with Accelerating Space Commerce, Exploration, and New Discovery (ASCEND).
  • Powered by the American Institute of Aeronautics and Astronautics (AIAA), ASCEND is recognized as the world's premier collaborative, outcomes-driven, interdisciplinary space event.
  • Just a year after launching the Care In Space initiative, we teamed up with prominent U.S. space organizations, bolstering our presence."